Complex Generics And Biosimilars Will Fuel Secular Demand
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 28 Analysts
Published
20 Jun 25
Updated
20 Aug 25
AnalystHighTarget's Fair Value
₹1,723.98
39.1% undervalued intrinsic discount20 Aug
₹1,050.40
1Y
-32.1%7D
-3.6%